Logo

American Heart Association

  18
  0


Final ID: MP1877

Eicosapentaenoic Acid (EPA) and GLP-1 Receptor Agonist Combination Enhanced Expression of Src Kinase and Related Pathways in Endothelial Cells during Inflammation

Abstract Body (Do not enter title and authors here): Background: The Src family of non-receptor protein tyrosine kinases participate in numerous cell-signaling pathways, including cell-cell and cell-extracellular matrix interactions. In endothelial cells (ECs), Src kinases, including c-Src, participate in angiogenesis. The omega-3 fatty acid eicosapentaenoic acid (EPA) delivered as icosapent ethyl (IPE) and certain GLP-1 receptor agonists (GLP1-RA) independently reduce cardiovascular (CV) risk through potentially multifactorial mechanisms. Yet, the combined effects of these agents on CV risk remain poorly understood.

Hypothesis: We suspected the combination of the GLP-1RA liraglutide (lira) and EPA would modulate protein expression, including c-Src, in ECs during inflammation.

Methods: Human umbilical vein ECs (HUVECs) were challenged with Ang II (100 nM) for 2 h, then treated with lira (50 nM) and/or EPA (40 µM) for 24 h. Global proteomic analysis performed by mass spectroscopy measured the relative expression levels simultaneously. Significant changes in expression between treatment groups >1-fold (based on log2 scale) were included in gene set enrichment analyses (GSEA). Previous studies identified increased heme oxygenase-1 (HO-1) levels with EPA and lira separately, so we measured HO-1 immunochemically as an indicator of drug activity.

Results: EPA, lira, and the combination all increased HO-1 levels >200% versus Ang II alone (p<0.01), demonstrating the activity of these agents in ECs. Compared with Ang II, there were over 40 significantly modulated proteins unique to the combination including c-Src, which increased 1.1-fold relative to Ang II alone (p = 7.59 × 10-5). GSEA revealed numerous pathways significantly affected by this increase, including “focal adhesion” (GO:0005925). Within this pathway, the combination treatment significantly modulated 10 proteins (including c-Src) of which 6 were similarly modulated by EPA alone while lira alone did not affect these proteins. Either EPA or the combination also increased levels of endoglin and several integrin family members (B1, B3, A2).

Conclusion: In ECs, EPA and lira enhanced expression of Src kinase and related signaling pathways and proteins compared to their separate effects. These pathways indicate the activation of EC migration and junctions in response to this combination. These potentially beneficial effects of EPA and a GLP-1RA combination on protein expression during inflammation may enhance CV protection compared to their separate actions.
  • Sherratt, Samuel  ( Mount Sinai Fuster Heart Hospital , Scarsdale , New York , United States )
  • Libby, Peter  ( Brigham and Womens Hospital , Beverly , Massachusetts , United States )
  • Dunbar, Richard  ( Amarin Pharma Inc. , Bridgewater , New Jersey , United States )
  • Bhatt, Deepak  ( Mount Sinai Fuster Heart Hospital , Scarsdale , New York , United States )
  • Mason, Preston  ( Brigham and Womens Hospital , Beverly , Massachusetts , United States )
  • Author Disclosures:
    Samuel Sherratt: DO have relevant financial relationships ; Employee:Elucida Research:Active (exists now) ; Speaker:Novartis:Past (completed) | Peter Libby: DO have relevant financial relationships ; Advisor:Amgen:Active (exists now) ; Research Funding (PI or named investigator):Novartis, Novo Nordisk, Genentech:Past (completed) ; Executive Role:XBiotech, Inc:Active (exists now) ; Executive Role:Soley Thereapeutics - financial interest:Active (exists now) ; Other (please indicate in the box next to the company name):TenSixteen Bio - financial interest:Active (exists now) ; Advisor:Polygon Therapeutics:Active (exists now) ; Advisor:PlaqueTec:Active (exists now) ; Advisor:Novartis:Active (exists now) ; Advisor:Olatec Therapeutics:Active (exists now) ; Advisor:Kowa Pharmaceuticals:Active (exists now) ; Advisor:Kancera:Active (exists now) ; Advisor:Elucid Bioimaging:Active (exists now) ; Advisor:CSL Behring:Active (exists now) ; Advisor:Caristo Diagnostics:Active (exists now) | Richard Dunbar: No Answer | Deepak Bhatt: DO have relevant financial relationships ; Advisor:Advisory Board: Angiowave, Antlia Bioscience, Bayer, Boehringer Ingelheim, CellProthera, Cereno Scientific, E-Star Biotech, High Enroll, Janssen, Level Ex, McKinsey, Medscape Cardiology, Merck, NirvaMed, Novo Nordisk, Repair Biotechnologies, Stasys, Tourmaline Bio:Active (exists now) ; Individual Stocks/Stock Options:Angiowave (stock options), Bristol Myers Squibb (stock), DRS.LINQ (stock options), High Enroll (stock);:Active (exists now) ; Other (please indicate in the box next to the company name):Site Co-Investigator: Cleerly.:Active (exists now) ; Royalties/Patent Beneficiary:Royalties: Elsevier (Editor, Braunwald’s Heart Disease);:Active (exists now) ; Researcher:Research Funding: Abbott, Acesion Pharma, Afimmune, Alnylam, Amarin, Amgen, AstraZeneca, Atricure, Bayer, Boehringer Ingelheim, Boston Scientific, CellProthera, Cereno Scientific, Chiesi, Cleerly, CSL Behring, Faraday Pharmaceuticals, Fractyl, Idorsia, Janssen, Javelin, Lexicon, Lilly, Medtronic, Merck, MiRUS, Moderna, Novartis, Novo Nordisk, Pfizer, PhaseBio, Regeneron, Reid Hoffman Foundation, Roche, Sanofi, Stasys, 89Bio;:Active (exists now) ; Royalties/Patent Beneficiary:Patent: Sotagliflozin (named on a patent for sotagliflozin assigned to Brigham and Women's Hospital who assigned to Lexicon; neither I nor Brigham and Women's Hospital receive any income from this patent);:Active (exists now) ; Other (please indicate in the box next to the company name):Other: Clinical Cardiology (Deputy Editor); Progress in Cardiovascular Diseases (Deputy Editor);:Active (exists now) ; Other (please indicate in the box next to the company name):Honoraria: American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org; Chair, ACC Accreditation Oversight Committee), Arnold and Porter law firm (work related to Sanofi/Bristol-Myers Squibb clopidogrel litigation), Baim Institute for Clinical Research (AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees), CSL Behring (AHA lecture), Duke Clinical Research Institute, Engage Health Media, HMP Global (Editor in Chief, Journal of Invasive Cardiology), Medtelligence/ReachMD (CME steering committees), MJH Life Sciences, Oakstone CME (Course Director, Comprehensive Review of Interventional Cardiology), Philips (Becker's Webinar on AI), Population Health Research Institute, WebMD (CME steering committees), Wiley (steering committee);:Active (exists now) ; Other (please indicate in the box next to the company name):Data Monitoring Committees: Acesion Pharma, Assistance Publique-Hôpitaux de Paris, Baim Institute for Clinical Research, Boston Scientific (Chair, PEITHO trial), Cleveland Clinic, Contego Medical (Chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ABILITY-DM trial, funded by Concept Medical; for ALLAY-HF, funded by Alleviant Medical), Novartis, Population Health Research Institute; Rutgers University (for the NIH-funded MINT Trial);:Active (exists now) ; Consultant:Consultant: Alnylam, Altimmune, Broadview Ventures, Corcept Therapeutics, Corsera, GlaxoSmithKline, Hims, SERB, SFJ, Summa Therapeutics, Worldwide Clinical Trials:Active (exists now) ; Other (please indicate in the box next to the company name):Board of Directors: American Heart Association New York City, Angiowave (stock options), Bristol Myers Squibb (stock), DRS.LINQ (stock options), High Enroll (stock);:Active (exists now) | Preston Mason: No Answer
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Vascular Inflammation and Resolution

Sunday, 11/09/2025 , 09:15AM - 10:25AM

Moderated Digital Poster Session

More abstracts on this topic:
A DHX38 Spliceosomal Mutation Impairs MYC Signaling, Cardiac Transcriptome Splicing, and Leads to Diastolic Dysfunction

Iwanski Jessika, Sarvagalla Sailu, Methawasin Mei, Van Den Berg Marloes, Churko Jared

A Prescription Trend Analysis of Antihypertensive Pharmacotherapy across Different Specialties in India

Vishavadia Krunal, Solanki Sandip, Kulkarni Girish, Prajapati Hiren

More abstracts from these authors:
You have to be authorized to contact abstract author. Please, Login
Not Available